Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesNo Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
Cancer Epidemiology, Biomarkers & Prevention, 09/14/09
Ahern TP et al. – Tamoxifen reduces recurrence risk among women treated for estrogen receptor–positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. The results provide evidence for a null association between drug–compromised CYP2D6 activity and breast cancer recurrence among tamoxifen–treated women.
Related Articles
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Relevance Score: 74%
Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09
Relevance Score: 72%
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09
Relevance Score: 72%
Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09
Relevance Score: 72%
Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09
Relevance Score: 72%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy
Langenbeck's Archives of Surgery, 12/16/09
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Expert Opinion on Investigational Drugs, 12/16/09
Plerixafor for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma
Annals of Pharmacotherapy, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor